Matinas BioPharma Holdings (MTNB) Change in Accured Expenses (2013 - 2026)
Matinas BioPharma Holdings (MTNB) posted quarterly Change in Accured Expenses of $242000.0 for Q1 2026, up 138.6% year-over-year from $101426.5 in Q1 2025, and up 310.43% quarter-over-quarter from -$115000.0 in Q4 2025.
Matinas BioPharma Holdings (MTNB) Change in Accured Expenses (2013 - 2026) Analysis & Trends
Matinas BioPharma Holdings (MTNB) has reported Change in Accured Expenses for 14 consecutive years, with $242000.0 the latest figure, recorded in Q1 2026.
- In Q1 2026, Change in Accured Expenses rose 138.6% year-over-year to $242000.0; the TTM figure through Mar 2026 stood at -$484000.0 (down 242.77% YoY), while the FY2025 annual figure was -$1.4 million, down 480.06% from the prior year.
- Change in Accured Expenses climbed to $242000.0 in Q1 2026 per MTNB's latest filing, from -$115000.0 in the prior quarter.
- Across five years, Change in Accured Expenses topped out at $2.5 million in Q2 2022 and bottomed at -$2.3 million in Q1 2023.
- Historically, Change in Accured Expenses has averaged -$126882.4 across 5 years, with a median of -$311000.0 in 2023.
- Annual changes were most pronounced in 2022 — Change in Accured Expenses slumped 1335.99% — and 2024, when it soared 346.3%.
- Matinas BioPharma Holdings' Change in Accured Expenses stood at -$597000.0 in 2022, then jumped by 47.91% to -$311000.0 in 2023, then jumped by 346.3% to $766000.0 in 2024, then plunged by 115.01% to -$115000.0 in 2025, then soared by 310.43% to $242000.0 in 2026.
- Business Quant data shows MTNB's Change in Accured Expenses at $242000.0 in Q1 2026, -$115000.0 in Q4 2025, and -$230000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Matinas BioPharma Holdings | 1.25 Mn | 437,566.66 | - | -190,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -190,000.00 |
| Jun 30, 2026 | -190,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Mar 31, 2026 | 242,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Dec 31, 2025 | -115,000.00 |
| Sep 30, 2025 | -230,000.00 |
| Sep 30, 2025 | -230,000.00 |
| Jun 30, 2025 | -381,000.00 |
| Jun 30, 2025 | -381,000.00 |
| Mar 31, 2025 | -627,000.00 |
| Mar 31, 2025 | -627,000.00 |
| Dec 31, 2024 | 766,000.00 |
| Dec 31, 2024 | 766,000.00 |
| Sep 30, 2024 | -404,000.00 |
| Sep 30, 2024 | -404,000.00 |
| Jun 30, 2024 | 604,000.00 |
| Jun 30, 2024 | 604,000.00 |
| Mar 31, 2024 | -610,000.00 |
| Mar 31, 2024 | -610,000.00 |